Mendus announces initial immunological data from CADENCE and VITAL-CML indicating vididencel improves immune competence across indications

What we doOur approachPipelineTechnology
About usManagementBoardClinical Advisory BoardCareers
NewsroomPress ReleasesEventsExpert PerspectivesPatient Stories
Investors

Back
Mendus announces initial immunological data from CADENCE and VITAL-CML indicating vididencel improves immune competence across indications
 8:00:00 AM

Keep reading
Mendus AB Interim Report July – September 2026Read